Count me in. It'd be great to have a community-driven evaluation instead of relying on individual papers with different assumptions!
------------------------------
William Wesolowski MS
Project Manager-Membership
SITC
Milwaukee WI
------------------------------
Original Message:
Sent: 03-20-2026 15:41
From: Lucy Macek
Subject: Pipeline Updates
Exactly. I'm thinking our SIG could run a small benchmarking project-compare the new predictors on a shared dataset and see if any of them hold up across tumor types.
------------------------------
Lucy Macek
Communications and Membership Coordinator
SITC
Milwaukee WI
Original Message:
Sent: 03-20-2026 15:39
From: William Wesolowski
Subject: Pipeline Updates
Yes! And what's interesting is how much the stability predictions change once you factor in antigen processing features. It's giving us a clearer picture of which candidates might drive actual T‑cell responses.
------------------------------
William Wesolowski MS
Project Manager-Membership
SITC
Milwaukee WI
Original Message:
Sent: 03-20-2026 15:37
From: Lucy Macek
Subject: Pipeline Updates
Have you had a chance to look at the new pipeline updates for predicting neoantigen stability? The latest models are starting to incorporate MHC–peptide complex dynamics instead of just affinity scores.
------------------------------
Lucy Macek
Communications and Membership Coordinator
SITC
Milwaukee WI
------------------------------